Hypertension in the elderly is a major risk factor for cardiovascular disease. We aimed to analyze determinants of blood pressure (BP) control across different age groups. Population of a large global survey on hypertension treatment and control including 18 927 patients was analyzed. A logistic regression analysis was conducted to estimate BP control rates and the prevalence of antihypertensive drug usage according to age. Systolic BP control decreased from 29.6% (95% confidence intervals (CI) 26.0;33.5) at 18 --40 years to 22. 4% (20.8;24.2) at 475 years (Po0.0001), and diastolic BP control increased from 31.6% (27.9;35.6) to 57.3% (55.2;59.3), respectively (Po0.0001). BP control was worse in diabetic patients, but did not differ substantially with co-morbid conditions, except for a better control in patients with myocardial infarction (MI) (Po0.05). The use of X3 antihypertensive drugs increased with age from 16.1 to 37.8% (Po0.0001) due to a more frequent use of loop diuretics (Po0.0001), thiazides (Po0.0001), angiotensin-converting enzyme (ACE) inhibitors (Po0.0001) and calcium channel blockers (Po0.0001). About one third of patients received non-guideline-recommended drug --drug combinations. BP control is largely unsuccessful with increasing age. Owing to frequent inadequacies in the combination of antihypertensive drugs, future guidelines and educational programs should devote increased attention to the choice of optimal drug --drug combinations in the elderly. Keywords: diuretics; elderly; drug --drug combinations; global; blood pressure control INTRODUCTION Hypertension represents a major risk factor for coronary events, stroke, congestive heart failure, peripheral artery disease, but also for cognitive impairment and dementia.
INTRODUCTION
Hypertension represents a major risk factor for coronary events, stroke, congestive heart failure, peripheral artery disease, but also for cognitive impairment and dementia. 1, 2 Elderly patients are more likely to develop cardiovascular (CV) events than the younger due to an elevated pulse pressure and accompanying co-morbidities. 3 Results from the HYVET (HYpertension in the Very Elderly Trial) have shown that antihypertensive treatment in patients 480 years of age not only reduced the rate of stroke by 34% and the rate of death from stroke by 45%, but also heart failure by 72% and CV death by 27%. 4 These data were essentially confirmed by a recently published meta-analysis from 420 studies in elderly patients (460 years) where antihypertensive therapy was associated with a decrease in CV and coronary heart disease mortality (relative risk 0.77) as well as cerebrovascular mortality and morbidity (relative risk 0.66). 5 These data indicate significant benefits of antihypertensive treatment in elderly patients, who represent the fastest growing demographic segment in society with the highest prevalence of hypertension. 6 Several epidemiological studies have suggested an inverse relationship between lower blood pressure (BP) levels and the risk of death in elderly patients suffering from conditions such as cancer, dementia, myocardial infarction (MI) or heart failure. These findings indicate that certain co-morbid conditions are associated with an elevated mortality risk and lower BP levels, but also highlight the risks of a more aggressive antihypertensive treatment in these vulnerable patients. 7, 8 These observations prompted us first, to analyze current levels of BP control and second, to investigate differences in the patterns of antihypertensive drug usage in different age groups. The analyses were conducted in a large international cohort of hypertensive patients treated by cardiologists.
PATIENTS AND METHODS
Patients and study procedures A large international survey was conducted in 26 countries in Europe, North America, Latin America, Middle East, Asia, Australia, and Morocco between September 2005 and March 2006. In all, 22 282 consecutive patients aged 418 years with currently treated or newly diagnosed arterial hypertension (seated systolic/diastolic BP (sSBP/sDBP) X140/90 mm Hg at the office visit measured after 5 min at rest) were screened, out of which 21 794 gave their written informed consent. Patients were enrolled by hospital-based cardiologists or in the outpatient cardiology setting. Furthermore, data on patient demographics, CV risk profile and co-morbidities, BP, antihypertensive and CV drug therapy were collected on a case report form as previously described. 9 Institutional review board approval was obtained in each participating center, and the study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the ICH-GCP (International Conference on Harmonization of Good Clinical Practice).
Data analysis
The present analysis was conducted in the subset of hypertensive patients receiving antihypertensive pharmacotherapy. Agespecific data on demographics, CV risk factors and co-morbidities as well as on systolic and diastolic BP values, and drug usage by drug class were analyzed. SBP and DBP control was defined as a BP o140 and o90 mm Hg for non-diabetics, and o130 and o80 mm Hg for diabetics, respectively. 10 Statistical analyses were conducted using SAS version 9. 
RESULTS

Patient characteristics
A total of 18 927 patients had a complete data set for the present analysis (Table 1) , about half of which were male. At a mean BMI of 28.9 kg m À2 , the waist circumference was 99.5 cm. Mean duration of hypertension was 9.0±7.5 years. There was an age-dependent increase in the prevalence of CV risk factors and co-morbidities such as dyslipidemia, diabetes, coronary artery disease and congestive heart failure. The only risk factor with an inverse correlation to age was smoking. There was no correlation to age for a family history of coronary artery disease and left ventricular hypertrophy (LVH).
BP values and control
There was an age-dependent increase in mean systolic and a continuous decline of mean diastolic BP with age ( Figure 1 ). Mean SBP increased from 144.9 ± 0.9 to 149.5 ± 0. Overall BP control was achieved in B20% of the total population, with no difference between age groups (P ¼ 0.68). Less patients with diabetes achieved BP control as compared with those without diabetes ( Table 2 ).
BP control rate in patients with CV risk factors/CV co-morbidities In the subgroups of patients with or without CV risk factors, or a history of stroke, MI, atrial fibrillation (Afib), LVH or CV co-morbidities, no difference in BP control rates was observed across the age groups (Table 3) . Furthermore, a history of MI appeared to be associated with higher BP control rates (Po0.05 for all age groups), whereas BP control rate was lower in patients with LVH (Po0.05 for the age group of 61 --75 and 475 years). In the age group of 18 --40 years, BP control rate appeared to be markedly higher as compared with the other age groups for patients with a history of MI (51.5 vs 21.7 --24.8%), Afib (40.8 vs 18.8 --21.1%) and 2/3 CV co-morbidities (35.2/36.5 vs 20.5 --25/ 19.3 --22.5%), but lower in patients with a history of stroke (11.5 vs 20.1 --22.3%).
Antihypertensive drug utilization The proportion of patients receiving therapy with antihypertensive monotherapy decreased with age from 44.2 to 22.6% (D 21.7%, Po0.0001), while the proportion of patients treated with three or more antihypertensive drugs increased from 16.1 to 37.8% (D 21.7%, Po0.0001). The proportion of patients with dual antihypertensive therapy was similar across the age groups ( Figure 2 ).
There was a strong inclination toward an increased use of loop diuretics (Po0.0001), thiazides (Po0.0001), angiotensin-converting enzyme (ACE) inhibitors (Po0.0001), and calcium channel blockers (CCBs) (Po0.0001) with age, while the use of angiotensin II receptor blockers or beta-blockers (BBs) remained stable throughout the age groups ( Figure 3 ). The presence of diabetes appeared to be associated with a higher usage of ACE inhibitors and loop diuretics across all age groups as compared with those without diabetes (Table 4) .
Overall, the prescription rate of dual combinations recommended by consensus guidelines did not change with increasing age (49.8% in the age group of 18 --40 years and 50.3% in the age group of 475 years). In contrast, there was a marked decrease in the prescription rate of BB þ angiotensin II receptor blockers and an increase in the prescription of loop diuretic-containing dual combinations ( Figure 4 ).
DISCUSSION
A BP reduction of only some millimeter mercury results in a steep reduction of CV events across age groups. 11 However, BP control was unsatisfactory at large in our study, with only half of treated hypertensive patients being controlled in countries with the best performance. Our data confirm insufficient BP control also in patients being treated by a cardiologist on a global scale with four out of five patients not achieving their target BP across all age groups. Control rates were even worse in diabetic patients for which a lower threshold of o130/80 mm Hg has been suggested, 12, 13 even though evidence appears to be weak to proof the necessity of going that low.
14 In our analysis, the presence of CV risk factors or a history of CV events did not alter these rates considerably, although patients with prior MI had better control rates. With respect to pharmacotherapy, we showed that the number of patients with multiple antihypertensive drugs increases considerably with age, largely by an increased use of CCbs, thiazides and loop diuretics.
BP control rates With increasing age, the accumulation of atherogenic risk factors results in vascular remodelling with aortic stiffening and large central elastic arteries. Therefore, hypertension in the elderly is mainly caused by a decrease in large artery compliance and characterized by the predominance of systolic hypertension with an increase in pulse pressure. 15 Consequently, SBP is a more accurate predictor of CV events and mortality than DBP in older patients. 16 Furthermore, a reduction in SBP has been identified as crucial for the clinical benefit of antihypertensive treatment, regardless of drug classes used. 17 In line with these pathophysiological considerations, our findings confirm an increased SBP and a decreased DBP resulting in an increased pulse pressure in the elderly despite the intensification of antihypertensive pharmacotherapy. Our data also confirm previous findings from other reports in Europe (and Canada), indicating BP control in only 20 --30% (47% in Canada) of treated patients, irrespective of age. 18, 19 However, SBP control rates in elderly patients have to been seen in the light of the fact, Treatment of hypertension in the elderly M Thoenes et al that target SBP (o140 mm Hg in non-diabetic patients) is rarely achieved even in clinical trials. Therefore, the recommendation to lower BP in the elderly to the same level as in younger patients (o140/90 mm Hg for non-diabetics) has been recently considered as a 'non-evidence-based' approach, even though the benefits of BP lowering in the elderly are undisputed. 5, 14 As much as low BP control rates are a concern in the most vulnerable population---the elderly, it also represents a major concern in the younger population, where prevention of long-term complications is of utmost importance. Data from the United States (NHANES) showed BP control rates of 74% in treated hypertensives aged 18 --40 years, but in only B20% of patients aged 35 --45 years in Europe. 18, 20 Our data indicate sufficient BP control in only a minority of patients (21%) aged 18 --40 years. The majority of these patients had not experienced major CV complications yet, but microalbuminuria and LVH (signs of end-organ damage) were already detected in 55 and 16% of patients, respectively. Furthermore, these patients are at an elevated CV risk, as evidenced by the frequent presence of a family history of coronary artery disease (28%), hyperlipidemia (23%) or cigarette smoking (40%). There is also evidence, that for a given increase in systolic or diastolic BP, the associated increase in CV risk is higher in younger as compared with older patients. This further highlights the urgent need to effectively control BP in younger hypertensive individuals. 21, 22 CV risk factors/CV co-morbidities and BP control Current guidelines for treatment of hypertension highlight the importance of a risk-based approach to hypertension management integrating not only the level of systolic and diastolic BP, but also the presence of CV risk factors, end-organ damage and CV/renal disease. 13, 14 Even though the recommended target BP is broadly similar for all patients (SBP o140 mm Hg, DBP o90 mm Hg), the individual patient risk should determine the approach to hypertension management in terms of time of initiation and the usage of antihypertensive pharmacotherapy. In our analysis, BP control rates in all age groups did not increase with an increasing number of CV co-morbidities and appeared to decrease with increasing CV risk such as smoking, hyperlipidemia, diabetes, family history of MI/CAD or a lack of physical exercise (not significantly). By looking at individual parameters, only the presence of an MI (Po0.05 in all age groups), but not of stroke, Afib and LVH seemed to be associated with a higher BP control Figure 2 . Number of antihypertensive drugs used by age. Adjusted for gender, diabetes and BMI; Po0.0001 for one drug; NS for two drugs; Po0.0001 for three drugs. Treatment of hypertension in the elderly M Thoenes et al rate. These findings may be explained by the fact that cardiologists might perceive an MI as the most relevant parameter for having BP controlled, but also point to a potential lack of perception for the increasing importance of a tight BP control in an aging population, where risk factors concomitant CV disease; and therefore, the overall risk for ischemic events accumulate.
Antihypertensive drug utilization There is a general trend for the usage of multiple antihypertensive drugs in the elderly, culminating at 38% of patients receiving three or more drugs to control their BP. These numbers are consistent with the rates of triple therapy necessary to reach BP goals in trials such as ALLHAT (32%), ACCOMPLISH (32%), SCOPE (49%) and INVEST (50%). 23, 24 However, BP control was low in our sample with only 20% reaching their BP target.
Potential reasons for the observed low BP control despite pharmacotherapy may lie in the fact that SBP appears to be more difficult to control than DBP, and an increasing age represents the strongest predictor of a lack of SBP control in treated hypertensives. 25 Our data confirm an age-dependent, linear increase in the prescription rate of triple drug combinations. Furthermore, diuretics, ACE inhibitors and CCBs---drug classes for which a clinical benefit has been documented in elderly patients with systolic hypertension (also for BBs)---were more frequently prescribed with increasing age. 26 --30 However, despite an increase in the number of drugs prescribed and the usage of efficacious drug classes, the age-related rise in SBP was not balanced by a more effective hypertension management as evidenced by an age-dependent decrease in SBP control rate, whereas DBP control rate increased to almost 60% at the age of 475 years.
A recent report from an Ontario administrative database suggested that---although there had been an increase in the use of polytherapy in elderly hypertensive patients without co-morbidities over the past decade---more than one quarter of the two drugs prescribed together have not been proven to have 31 This is in line with our data, where about one third of the patients received a combination of RAS (renin-angiotensin-aldosterone system)-blocking agent and a BB. International treatment guidelines in force at the time of the conduct of this survey do not generally recommend this particular combination for hypertension treatment unless there is compelling indications for its use.
10,32 However, we have not considered other national treatment guidelines within the scope of our international patient sample. The predominant prescription of RAS-blocking agents and BBs might be attributed to the established efficacy of these drug classes for CV protection as perceived by the treating cardiologist or specialist. Because this inadequacy might contribute to suboptimal BP control rates, we suggest that future guidelines and educational programs devote increased attention to the choice of optimal polytherapy combinations, particularly in elderly patients.
What is known about this topic
Even though epidemiological studies suggested an inverse relationship between lower blood pressure levels and mortality, recent data indicate a significant benefit of antihypertensive treatment in the elderly. Hypertension in the elderly is mainly due to an increase in systolic blood pressure, which appears to be more difficult to control.
What this study adds Our study confirms low blood pressure control rates in only B20% of patients and irrespective of age in a large international sample of patients.
Blood pressure control appears to be higher in patients with a history of myocardial infarction, but not in those with concomitant risk factors or concomitant cardiovascular disease. Insufficient blood pressure control in the elderly is observed despite the increased use of dual of triple therapies and the prescription of drug classes, which have shown to be effective in controlling systolic blood pressure, such as diuretics, ACE inhibitor or calcium antagonists. This study provides an updated view on blood pressure control rates on a worldwide basis and across different age groups.
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